Best available Treatment (BAT) clinical trials

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

This study looks at a new medicine called Axatilimab for children aged 2-17 with a condition called chronic Graft-versus-Host Disease (cGVHD). These children have already tried at least two other treatments. The study compares Axatilimab with existing best treatments to see which works better.